Results 221 to 230 of about 1,045,429 (295)
Molecular Oncology, EarlyView.Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou +12 more
wiley +1 more source
Emerging Antimicrobial Resistance in Klebsiella pneumoniae: A Molecular and Antibiogram Insight From the Beef Value Chain in Bangladesh. [PDF]
MicrobiologyopenUddin MS +11 more
europepmc +1 more source
Interpreting the effects of DNA polymerase variants at the structural level
Molecular Oncology, EarlyView.Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi +7 more
wiley +1 more source
Understanding the role of knowledge and attitudes of community pharmacy staff in non-prescribed antibiotic dispensing practices in Bangladesh: a cross-sectional study. [PDF]
BMJ OpenSultana Samapti MM +6 more
europepmc +1 more source
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
School as Marketplace for Promoting Unhealthy Snack Consumption Among Children in Northern Thailand. [PDF]
InquiryPudsa B +3 more
europepmc +1 more source
Molecular cancer prevention: Intercepting disease
Molecular Oncology, Volume 20, Issue 6, Page 1392-1397, June 2026.Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source
Cultivating hope: reframing the 'heart-sink' consultation. [PDF]
Br J Gen PractMustafa M +3 more
europepmc +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source